• RATHAI RAJAGOPALAN 1Department of Pharmacology, M.S.Ramaiah medical college, MSR Nagar, MSRIT post, Bangalore, 560054, India
  • PRIYADARSHINI M.DEODURG Department of Pharmacology, Khaja Banda Nawaz institute of medical sciences, Gulbarga, 585104, India.
  • SRIKANTH 2Department of Pharmacology, Khaja Banda Nawaz institute of medical sciences, Gulbarga, 585104, India


Randmized controlled trials, study design, randomization, clinical research


Randomized controlled trials are considered to be the gold standard in clinical studies to establish level of evidence in medical research. But, they are not easy to conduct and various other aspects have to be looked into. Randomization offers each enrolled subject equal chance of being allocated to the intervention and the control groups. Randomized control trial (RCT) is most powerful tool in clinical research. In this, subjects  are assigned to different groups of interventions by chance for comparison. RCT is only study design which can help us evaluate a new treatment.  By assigning participants to different intervention groups by chance, comparison between the interventions groups is made. Purpose of randomization is to make the treatment groups comparable, eliminates the source of and it ensures that the difference in groups is only due to trial treatments. In this article, we review randomized control trial with special emphasis on various types of randomized controlled trials, their characteristics, the process of randomization, and advantages and drawbacks of randomized controlled trials.


Key words:Randmized controlled trials, study design, randomization, clinical research


Download data is not yet available.


) Available from http://www.cebm.net/index.aspx?o=1116. [Last accessed on June 1st 2012 at 6.00pm].

Ranjith G, Interferon-α-induced depression: when a randomized trial is not a randomized controlled trial, Psychother Psychosom 2005;74(6):387.

Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769–82.

Peter Armitage. International Journal of Epidemiology 2003;32:925–28.

Meldrum ML. A brief history of the randomized controlled trial. From oranges and lemons to the gold standard. Hematol Oncol Clin North Am 2000;14:745–60.

Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.

Anita S Acharya, Anupam Prakash, Aruna Nigam, Pikee Saxena. Scientific study designs for research: an overview. Indian journal of medical specialities 2012;3(2):191-94 (modified).

Shraddha Parab, Supriya Bhalerao. Study designs. International Journal of Ayurveda Research 2010;1(2):128-31.

Available from http://www.fda.gov/downloads/regulatory information/guidances/ucm125912. pdf. [Last accessed on 20th march 2013 at 4 pm].

Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: Comparative study of articles indexed in PubMed. BMJ 2010;340:c723.

Stolberg HO, Norman G, Trop I. Randomized controlled trials. Am J Roentgenol 2004;183:1539–44.

Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601–5.

Sackett DL, Gent M., Controversy in counting and attributing events in clinical trials, N Engl J Med 1979;301:410-12.

Fletcher RH, Fletcher SW, Wagner EH., Clinical epidemiology: the essentials, 3rd ed. Baltimore, MD: Williams & Wilkins;1996.

Guyatt G, Sackett D, Taylor DW, Chong J, Roberts RS, Pugsley S. Determining optimal therapy-randomized trials in individual patients, N Engl J Med 1986;314:889-92

Woods KL., Mega-trials and management of acute myocardial infarction, Lancet 1995; 346:611-14.

Louis TA, Lavori PW, Bailar JC III, Polansky M., Crossover and self controlled designs in clinical research. In: Bailar JC III, Mosteller F, editors. Medical uses of statistics, 2nd ed. Boston, MA: New England Medical Journal Publications;1992. p. 83-104.

Greenland S, O’Rourke K. Meta-analysis. In:Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins;2008. p. 652-82.

Donner A, Klar N: Design and Analysis of Cluster Randomization Trials in Health Research. London: Arnold; 2000.

Duffy SW. Interpretation of the breast screening trials: A commentary on the recent paper by Gotzsche and Olsen. The Breast 2001;20:209-12.

Kalish LA, Begg GB. Treatment allocation methods in clinical trials a review. Stat Med 1985;4:129-44.

Altaman DG, Bland JM. Statistics notes. Treatment allocation in controlled trails: Why randomize? BMJ 1999;318:1209.

Weir CJ, Lees KR. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial. Stat Med 2003;22:705-26.

Lachin JM, Matis JP, Wei LJ. Randomizations in clinical trails, conclusions and recommendations. Control Clin Trails 1988;9:365-74.

Frane JW. A method of biased coin randomization, its implementation and validation. Drug Inf J 1998;32:423-32.

Altaman DG Bland JM. How to use randomize. BMJ 1999;319:703-4.

Lachin JM, Matis JP, Wei LJ. Randomizations in clinical trials, conclusions and recommendations. Control Clin Trails 1988;9:365-74.

Zalene M. Randomized consent designs for clinical trails: An upadate. Stat Med 1990;9:645-56.

Kalish LA, Begg GB. Treatment allocation methods in clinical trials a review. Stat Med 1985;4:129-44.

De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. New Engl J Med 2004;351:1250–1.



How to Cite

RAJAGOPALAN, R., P. M.DEODURG, and SRIKANTH. “OVERVIEW OF RANDOMIZED CONTROLLED TRIALS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 6, no. 3, July 2013, pp. 32-33, https://innovareacademics.in/journals/index.php/ajpcr/article/view/175.




Most read articles by the same author(s)